Zobrazeno 1 - 10
of 262
pro vyhledávání: '"Marcela V Maus"'
Autor:
David Millar, Rebecca Larson, Marcela V Maus, Amanda A Bouffard, Matthew J Frigault, Stefanie R Bailey, Mark B Leick, Michael C Kann, Cameron J Turtle, Trisha Berger, Kathleen Gallagher, Korneel Grauwet, Harrison Silva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved CAR-T cell products use the FMC63-based αCD19 single-chai
Externí odkaz:
https://doaj.org/article/ecfec6545a5648c1bf0005393d1e6f09
Autor:
Marcela V Maus, Mahmoud R Gaballa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Externí odkaz:
https://doaj.org/article/cfa572dcc0b74214b8992a5e0f26a319
Autor:
Marc Wehrli, Marcela V Maus, Matthew J Frigault, Mark B Leick, Nora Horick, Paul O'Donnell, Kathleen Gallagher, Yi-Bin Chen, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/10c1819e606a475e82bdbd71febdb0e1
Autor:
Carl H June, David M Barrett, Stephan A Grupp, Rong Fan, Marcela V Maus, Zhiliang Bai, Stefan Lundh, Dongjoo Kim, Steven Woodhouse, Regina M Myers, Pablo G Camara, J Joseph Melenhorst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the use of donor-generated allog
Externí odkaz:
https://doaj.org/article/d1c8e9cf34dd480380636e72e6720295
Autor:
Marcela V Maus, Jason Plotkin, Gopinadh Jakka, Guillaume Stewart-Jones, Isabelle Rivière, Taha Merghoub, Jedd Wolchok, Christoph Renner, Michel Sadelain
Publikováno v:
Molecular Therapy: Oncolytics, Vol 3, Iss C (2016)
Chimeric antigen receptors (CARs) are synthetic receptors that usually redirect T cells to surface antigens independent of human leukocyte antigen (HLA). Here, we investigated a T cell receptor-like CAR based on an antibody that recognizes HLA-A*0201
Externí odkaz:
https://doaj.org/article/0fec421582a340cfbea2567b5dda0878
Publikováno v:
Annual Review of Cancer Biology. 7:23-42
Chimeric antigen receptor (CAR) T cell therapy has emerged as a new opportunity for cancer treatment; however, resistance can occur due to intrinsic (T cells), extrinsic (tumors), or acquired (tumors) factors. In many cases, the knowledge of these me
Autor:
Matthew J. Frigault, Michael R. Bishop, Jacalyn Rosenblatt, Elizabeth K. O’Donnell, Noopur Raje, Daniella Cook, Andrew J. Yee, Emma Logan, David E. Avigan, Andrzej Jakubowiak, Kit Shaw, Heather Daley, Sarah Nikiforow, Faith Griffin, Christine Cornwell, Angela Shen, Christopher Heery, Marcela V. Maus
Publikováno v:
Blood Advances. 7:768-777
Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This si
Autor:
Kimberly R. Hagel, Rand Arafeh, Sydney Gang, Taylor E. Arnoff, Rebecca C. Larson, John G. Doench, Nathan D. Mathewson, Kai W. Wucherpfennig, Marcela V. Maus, William C. Hahn
Publikováno v:
Cancer Research. 83:613-625
Chimeric antigen receptor (CAR) T-cell therapy can lead to dramatic clinical responses in B-cell malignancies. However, early clinical trials with CAR T-cell therapy in non–B-cell malignancies have been disappointing to date, suggesting that tumor-
Autor:
Akshay Sharma, Stephanie Farnia, Folashade Otegbeye, Amy Rinkle, Jugna Shah, Nirali N. Shah, Saar Gill, Marcela V. Maus
Publikováno v:
Transplantation and Cellular Therapy. 28:795-801
Autor:
Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, Maria Almena-Carrasco, Agnieszka Jozwik, Sylvain Fouliard, Yasmina Adimy, Julia Geronimi, Charlotte Graham, Nitin Jain, Marcela V. Maus, Mohamad Mohty, Nicolas Boissel, Takanori Teshima, Koji Kato, Reuben Benjamin, Svetlana Balandraud
Publikováno v:
Cancer Research Communications. 2:1520-1531
Background: UCART191 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. Methods: UCART19 was administered to 25 adult patients with relapsed or refractory